Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $40.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Eloxx Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Eloxx Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | 10% Owner | 361,578Indirect | Jun 17, 2026 | 2 |
| Rubin Steven D | Director | 14,625 | Jun 10, 2026 | 2 |
| Kjellson Nina S | Director | – | Jun 10, 2026 | 1 |
| Webster Stephen W | Director | – | Jun 10, 2026 | 1 |
| Walts Alan Edmund | Director | 15,567 | Jun 10, 2026 | 2 |
| Aggarwal Sumit | President and CEO | 1,672,756 | Jun 10, 2026 | 2 |
| Coastlands Capital LP | 10% Owner | 0Indirect | May 29, 2026 | 1 |
| Androski Lindsay | Director | 15,750 | Jan 28, 2025 | 0 |
| Kariv Tomer | Director | – | Jan 31, 2023 | 0 |
| Modur Vijay | HEAD OF R&D | 154,953 | Jan 27, 2023 | 0 |
| Parekh Rajesh B | Director | – | Jun 17, 2022 | 0 |
| Nussbaum Ran | Director | – | Jun 17, 2022 | 0 |
| Veinrib Gadi | Director | – | Jun 17, 2022 | 0 |
| Avnur Zafrira | Director | – | Jun 17, 2022 | 0 |
| Seehra Jasbir | Director | – | Jun 17, 2022 | 0 |
| Geffken Daniel E. | INTERIM CFO | 50,000 | Dec 1, 2021 | 0 |
| Belloff Neil S. | COO, GENERAL COUNSEL &CORP SEC | 32,699 | Jul 30, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 (view filing) | Nov 29 | 2 days | Geffken Daniel E.INTERIM CFO | PPurchase | +50.0K | $0.72 | +$36.0K | New position50.0K after |